10/31/2013 8:51:51 AM
This morning, Array Biopharma will outline its plans to investors to get its first wholly-owned drug, a treatment for the blood cancer multiple myeloma, approved by the Food and Drug Administration. Codenamed ARRY-520, the medicine is a exciting because it is a new class of medicine, completely different from the immunomodulatory agents, including thalidomide, Revlimid, and Pomalyst, all made by Celgene CELG -1.83%, and the proteasome inhibitors Velcade, sold by Takeda, and Kyprolis, from Amgen AMGN -0.32%. “In patients that have failed everything we believe 520 can offer benefit,” says Ron Squarer, Array’s chief executive.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by